Can a simple blood test predict immunotherapy success in skin cancer?
NCT ID NCT07064330
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study is enrolling 30 people with a common skin cancer called cutaneous squamous cell carcinoma who are about to start treatment with the immunotherapy drug cemiplimab. Researchers will use advanced lab techniques to analyze immune cells and molecules in participants' blood and tumor samples. The goal is to find biological markers that can tell doctors ahead of time who is likely to respond well to the drug and who might develop serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cemiplimab
- What this could lead to
- If successful, this could help doctors predict which patients will benefit from cemiplimab and who might experience side effects, leading to more personalized treatment for skin cancer.
- What could go wrong
- This is a small, early-stage biomarker study (30 participants) that aims to observe and measure, not to test a new treatment. The findings may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Complejo Asistencial Universitario de Salamanca
RECRUITINGSalamanca, Salamanca, 37007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny biopsy outsmart skin Cancer's spread?
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- Blood clot marker may predict immunotherapy success in advanced skin cancer
- New drug aims to fight skin cancer in transplant patients
- Could a 2-Week radiation course replace longer treatment for skin cancer?
- French study tracks Real-World skin cancer care for 1500 patients